SCHEMBL23924238

SCHEMBL23924238

O=C(Nc1cccc2ccccc12)[C@H]1CN(C(=O)O)C[C@@H]1c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP7 O15540 2/20 0.55
KDM4E B2RXH2 12/20 0.55
FABP3 P05413 1/20 0.52
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
ALDH1A1 P00352 7/20 0.45
HSD17B10 Q99714 6/20 0.45
POLB P06746 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.44
MAPT P10636 1/20 0.44
USP2 O75604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23924250 1.00 FABP7 (0.55) FABP7KDM4EFABP3MEN1KMT2A
SCHEMBL23924239 1.00 FABP7 (0.55) FABP7KDM4EFABP3MEN1KMT2A
SCHEMBL23924227 0.89 KDM4E (0.47) FABP7KDM4EFABP3MEN1KMT2A
SCHEMBL23924337 0.89 KDM4E (0.47) FABP7KDM4EFABP3MEN1KMT2A
SCHEMBL23924282 0.88 TRPV1 (0.47) FABP7KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL23924170 0.88 TRPV1 (0.47) FABP7KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL23924172 0.88 TRPV1 (0.47) FABP7KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL23924493 0.88 TRPV1 (0.47) FABP7KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL23924118 0.88 TRPV1 (0.47) FABP7KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL28932943 0.85 TACR1 (0.57) FABP7KDM4EFABP3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 FABP7 666/4885KDM4E 2961/4885FABP3 1206/4885
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 FABP7 666/4885KDM4E 2961/4885FABP3 1206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.